Displaying 71 (all) recruiting clinical trials.
-
NAUTIKA1: A Multicenter Phase II Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients with Resectable Stages IB-III Non-Small Cell Lung Cancer
Study ML41591, is an umbrella trial that will evaluate the efficacy and safety of targeted therapies in patients with resectable Stage IA2, IB, II, IIIA ... -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) -
Alexion NEPH-202 Ravulizumab trial
Chronic kidney disease (CKD) has become a worldwide public health issue due to its high incidence, poor prognosis, and substantial economic burden. When not properly ... -
Cannabidiol for Treating PTSD symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid with TBI: A Placebo-controlled RCT with Neural-circuit centered Precision Medicine Prediction of Response.
This will be a randomized placebo controlled parallel dose finding study. The purpose of this project is to test the efficacy of cannabidiol (CBD) as ... -
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
This is a randomized non-inferiority trial of 6-months of gonadotropin releasing hormone (GnRH) agonist and bicalutamide plus radiation therapy (RT) versus 6-months of Darolutamide plus ... -
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment With or Without Dialysis PHYOX7
The aim of this study is to evaluate DCR-PHXC in participants with PH1 or PH2 and severe renal impairment, with or without hemodialysis or peritoneal ... -
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax ... -
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
DAY101 is an oral, selective, small-molecule, Type II pan-RAF kinase inhibitor that is being developed by DOT Therapeutics-1 Inc. (Day One, the Sponsor) for the ... -
Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations (IND 156083)
A Phase II randomized trial will be initiated to evaluate efficacy of FGF-2 in treatment of chronic non-healing tympanic membrane perforation. This study is a ... -
A Phase 2 Open-Label Multicenter Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6
This is a Phase 2, global, multicenter, open-label, cohort study designed to evaluate the antitumor activity, safety and tolerability, HRQoL, PK, and pharmacodynamics of ALKS ...